NMRA Stock Analysis: Buy, Sell, or Hold?
NMRA - Neumora Therapeutics, Inc. Common Stock
$1.49
-0.07 (-4.49%)
▼
5d:
-7.45%
30d:
+2.05%
90d:
-33.18%
WAIT
LOW Confidence
Analysis Updated: Jul 24, 2026 12:00 AM ET
Earnings: Aug 05, 2026
9d
Get Alerted When NMRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NMRA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NMRA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NMRA is currently trading at $1.49, which is considered oversold relative to its 30-day fair value range of $1.53 to $1.67.
Technical Outlook: Technically, NMRA is in a strong downtrend. The price is currently testing key support at $1.46. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: NMRA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (92th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $6.28 (+321.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NMRA is in a strong downtrend. The price is currently testing key support at $1.46. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: NMRA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (92th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $6.28 (+321.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.53 -
$1.67
Company Quality Score
44/100
(HOLD)
Options IV Signal
92th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
41.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 92th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 321.6% below Wall St target ($6.28)
Trading Range Analysis
30-Day Trading Range
$1.53 -
$1.67
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.56
(37.8%)
Support & Resistance Levels
Support Level
$1.46
Resistance Level
$1.72
Current Trend
Strong Downtrend
Technical data as of
Jul 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.02
Wall Street Target
$6.28
(+321.6%)
Share & Embed Analysis
Last updated: July 25, 2026 9:32 PM ET
Data refreshes hourly during market hours. Next update: 10:32 PM
Data refreshes hourly during market hours. Next update: 10:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Daljit Singh Aurora
SELL
6165 shares
2026-02-17
Joshua Pinto
SELL
5967 shares
2026-02-17
Michael Lee Milligan
SELL
1436 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$415 | 49 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$280 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$114 | 53 HOLD |